Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by Conquistador1on Jan 30, 2018 10:18am

201 Views

Post# 27462015

RE:Nas listing would be best in the long run

NONSENSE! Are you a shill for the company? The China deal is small potatoes. It is not a well known biopharma. Management has at every turn, hurt the shareholders. Look at the last crappy financing that they did with Canaccord. The share consolidation is not being done for the benefit of shareholders. Don't be fooled!

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario